News | June 16, 2022
Enko advances Enkompass platform through DNA-encoded library technology
Large datasets will train machine learning models and speed up agile discovery of novel crop protection solutions
Large datasets will train machine learning models and speed up agile discovery of novel crop protection solutions
Group 4 Medulloblastoma is a rare disease that mostly affects pediatric patients, in which aberrant SRC signaling was identified as a hallmark of the disease
Doubling of median overall survival seen in QuANTUM-First results presented at EHA Presidential Symposium
Amarex Clinical Research guides its client to phase II of FDA trials
Centre of Excellence at Kharel comprises Skill-building Centre and Primary, Secondary and Higher Secondary schools
TP-3654 is currently being evaluated in a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with intermediate or high-risk primary or secondary myelofibrosis.
If approved, Tafinlar + Mekinist may offer a potential new standard-of-care for pediatric patients with this brain cancer
he approved product has an estimated market size of US$ 83 million for the twelve months ending April 2022, according to IQVIA.
Scemblix (asciminib) continues to show superior efficacy with more-than-two-fold improvement in major molecular response rate vs. Bosulif (bosutinib) at 96 weeks
he Phase 2 TIDAL data generated to date continue to highlight zandelisib's therapeutic profile and the potential to benefit patients
Subscribe To Our Newsletter & Stay Updated
